Accro Bioscience, a clinical-stage biotechnology firm, has successfully closed a $50 million Series C financing round to advance its innovative treatments for immune-mediated diseases. The funding, led by prominent healthcare investor OrbiMed, will primarily support the next phase of clinical trials for its lead drug candidate, AC-101. This capital infusion marks a significant step forward in developing new therapies for patients suffering from conditions like Ulcerative Colitis.
Strategic Investment to Propel Clinical Trials
The financing was spearheaded by OrbiMed, with significant contributions from new investors TCG Crossover, LAV, and Cenova Capital. Existing investors, including Shenzhen Capital Group and Oriza Holdings, also participated, demonstrating continued confidence in the company's direction. This substantial investment underscores the growing interest in Accro Bioscience's unique therapeutic platform and its potential to address unmet medical needs.
Proceeds from this round are earmarked to fund the pivotal Phase IIb clinical trial of AC-101 for the treatment of Ulcerative Colitis. Beyond this primary objective, the capital will also be used to accelerate the development of other novel therapeutic candidates within the company's pipeline. This strategic allocation of resources aims to solidify Accro's position as a leader in inflammation and immunology (I&I) disease therapies.
Pioneering a Novel Therapeutic Approach
AC-101 is a novel and selective inhibitor of RIPK2, a key protein involved in the body's inflammatory response. Dysregulation of the NOD/RIPK2 signaling pathway is implicated in several autoimmune diseases, making it a promising target for therapeutic intervention. Accro Bioscience developed AC-101 through its proprietary drug discovery platform, which focuses on regulatory cell death and inflammation.
The drug candidate has already shown a favorable safety and pharmacokinetic profile in completed Phase I studies conducted in Australia and China. Furthermore, a Phase Ib/IIa proof-of-concept study in Chinese patients with moderate-to-severe Ulcerative Colitis has been successfully concluded. The company has also received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration to proceed with a Phase II trial.
Leadership and Investor Confidence
Dr. Xiaohu (Jason) Zhang, Co-founder and CEO of Accro Bioscience, affirmed the company's commitment to delivering innovative oral treatments for patients. He expressed deep gratitude for the investors who share and continuously support the company's vision for transforming patient care. This backing is crucial as the company advances its clinical programs and expands its research efforts in immune-mediated diseases.
Steven Wang, a Partner at OrbiMed, highlighted the firm's strong impression of Accro Bioscience's innovative pipeline and scientific expertise. He noted that the team's proven track record of strong execution was a critical factor in their decision to lead the investment. OrbiMed is enthusiastic about partnering with Accro to accelerate its global clinical development and bring new therapies to market.
Market Context and Future Outlook
Accro Bioscience is dedicated to pioneering the discovery and commercialization of new treatments for inflammatory and autoimmune conditions. The company's strategy centers on targeting the molecular mechanisms of regulatory cell death to create paradigm-shifting therapies. Its robust pipeline of first-in-class compounds holds significant potential for addressing complex diseases with high unmet needs.
The leadership of OrbiMed, a premier healthcare investment firm with over $19 billion in assets, lends significant weight to this financing. OrbiMed's global presence and extensive resources are expected to provide valuable support for Accro's growth and clinical ambitions. This partnership reflects a shared goal of building world-class healthcare companies that deliver transformative medical solutions.
This $50 million financing round represents a pivotal achievement for Accro Bioscience, providing the necessary capital to advance its lead candidate, AC-101. The strong backing from a syndicate of esteemed investors validates the company's scientific approach and its potential to impact the treatment landscape for Ulcerative Colitis. With this support, Accro is well-positioned to continue its mission of developing groundbreaking therapies for patients with debilitating immune-mediated diseases.